Objectives: The objective of this study was to investigate the significance of molecular classification in guiding treatment decisions for patients with endometrial cancer (EC) or atypical hyperplasia (AH) undergoing fertility-sparing treatment (FST), particularly for those with non-NSMP subtypes. Methods: We conducted a retrospective cohort study involving EC/AH patients undergoing FST and molecular classification using next-generation sequencing at Peking University People’s Hospital between June 2020 and September 2023. Results: A total of 118 EC/AH patients were included, including 92 cases with NSMP, 11 with MMRd, 11 with POLEmut, and 4 with p53abn. (1) Of the 11 patients with MMRd, 6 achieved a complete response (CR) with 1 case receiving progestin, 3 cases showed insensitivity to the initial progestin before transitioning to a combined regimen of progestin and a PD-1 inhibitor, and 2 cases initially received progestin plus a PD-1 inhibitor. There were no significant differences in the cumulative CR rates between the MMRd and NSMP subgroups but a trend of a lower relapse-free-survival (RFS) rate for the MMRd subgroup (p = 0.074). (2) Of the 11 cases with POLEmut, 10 achieved CR but 4 relapsed. There was also a trend for a lower RFS rate in the POLEmut patients (p = 0.069) compared with the NSMP subgroup. (3) Three of the four patients with p53mut achieved CR after treatment with the GnRHa plus LNG-IUS regimen. Conclusion: The selection of appropriate regimens may improve FST outcomes in EC/AH patients with molecular classification of non-NSMP subtypes. Immunotherapy is an effective fertility-preserving approach for patients with MMRd.
Introduction: We aimed to assess the safety of continuous uterus‐preserving treatment among patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) who gave birth after progestin‐based fertility‐sparing treatment (FST). Material and Methods: From January 2005 to June 2020, we conducted a retrospective cohort study at Peking University People's Hospital, China, comprising 212 patients with EC or AEH who underwent FST. The participants were categorized into two groups based on the reproductive outcome of live birth. Risk factors were analyzed for disease recurrence in the entire cohort, and additional analysis was conducted on postpartum recurrence specifically in the live birth group. Results: Of 212 eligible patients, 73 had a live birth, and 139 did not have a live birth after FST. Multivariable Cox analysis showed that live birth significantly reduced the risk of disease recurrence (HR 0.326, p = 0.011), while insulin resistance was identified as an adverse factor (HR 3.216, p = 0.014). Except for two patients who underwent hysterectomy, among 71 patients undergoing uterus preservation after live birth, five (7%) patients experienced disease relapse (two EC and three AEH) after a median follow‐up of 26 (11, 47.5) months. Four out of these five patients with recurrence achieved a complete response after a second round of FST. Eight other patients (11.3%) experienced hyperplasia without atypical (EH) after live birth. Potential risk factors for postpartum recurrence of EC/AEH included irregular menstruation (80% vs. 39%; p = 0.153), abnormal ultrasonographic findings (60% vs. 18.6%; p = 0.065), and increased endometrial thickness (0.82 cm vs. 0.55 cm; p = 0.017). While postpartum maintenance therapy was identified as a protective factor against recurrence (0% vs. 62.5%; p = 0.012). Notably, patients with postpartum recurrence may achieve a complete response with repeat FST. Conclusions: Although live birth was associated with improved recurrence‐free survival in patients with EC or AEH receiving FST, postpartum recurrence remains a concern. Irregular menstruation and abnormal ultrasound findings were identified as key risk factors for recurrence, while maintenance therapy exhibited a protective effect. These findings highlight the need for vigilant postpartum monitoring in this population.
19 March 2026 in Clinical and Experimental Obstetrics & Gynecology
Background: The incidence of endometrial cancer (EC) has been rising annually, and many young patients wish to preserve their reproductive potential. This study aims to evaluate the impact of a whole-course management model on treatment adherence and efficacy among patients with early-stage EC and atypical endometrial hyperplasia (AEH) seeking fertility preservation. Methods: This retrospective cohort study involved 162 patients diagnosed with EC or AEH who underwent fertility-preserving treatment at Peking University People’s Hospital between July 2010 and December 2023. Patients were divided into two groups: the control group (n = 80; diagnosed from July 2010 to June 2019) received conventional disease management, while the experimental group (n = 82; diagnosed from November 2022 to December 2023) received a physician–nurse collaborative whole-course management model. In the experimental group, each patient was assigned a dedicated nurse responsible for monitoring treatment, ensuring protocol adherence, and promptly reporting any abnormalities or disease progression to physicians. Data from both groups were collected over a one-year follow-up period. Results: No statistically significant differences in baseline characteristics, including residence, income, occupation, education, and treatment regimens, were observed between the two groups (p > 0.05). The experimental group exhibited significantly higher follow-up rates at 3 months (91.5% vs. 93.8%, p = 0.578), 6 months (64.6% vs. 46.3%, p = 0.019), and 1 year (64.6% vs. 30.0%, p < 0.001), as well as greater patient satisfaction (68.3% “very satisfied” vs. 17.5% “very satisfied”, p < 0.001). The median time to complete remission was shorter in the experimental group (6.2 months vs. 10.4 months, p = 0.007), and no disease progression was observed. Conclusions: The physician–nurse collaborative whole-course management model is effective for patients with EC and AEH undergoing fertility preservation. It significantly enhances treatment adherence, patient satisfaction, and clinical outcomes.
Background: Young patients with early-stage endometrial cancer (EC) or atypical endometrial hyperplasia (AEH) pursuing fertility preservation currently lack reliable non-invasive predictors of response to progestin therapy, relying instead on repeated invasive biopsies that may compromise endometrial receptivity. We aimed to identify biologically distinct progestin-response subtypes and develop a serum proteomics–based predictive system.Methods: In a retrospective cohort of 349 EC/AEH patients undergoing fertility-sparing treatment, unsupervised clustering was performed using comprehensive clinicopathological variables. Serum proteomic profiling was conducted in a subset of 97 patients to identify subtype-associated protein signatures and construct a serum-based predictive panel.Findings: Unsupervised clustering identified three biologically distinct subtypes with differential sensitivity to progestin therapy: a progestin-sensitive subtype (cluster 1), an immune-activated subtype (cluster 2), and a metabolic dysfunction subtype (cluster 3). Cluster 1 was characterized by favorable metabolic profiles and lymphocyte-mediated immune activation; cluster 2 showed enrichment of innate immunity and chronic inflammatory pathways; cluster 3 exhibited severe lipid metabolic dysregulation, insulin resistance and immune suppression. Based on subtype-specific proteomic features, a novel nine-protein serum panel was established. This panel demonstrated robust predictive performance for complete remission (CR) in both training (AUC = 0.880) and validation (AUC = 0.856) cohorts. Integration with conventional clinical parameters further improved prediction accuracy (AUCs up to 0.924 and 0.977). Finally, longitudinal analysis of serial serum samples from 12 patients confirmed the panel’s ability to dynamically monitor treatment response and CR status during follow-up.nterpretation: We define three distinct progestin-response subtypes in EC/AEH and developed and validated a non-invasive nine-protein serum panel that accurately predicts and monitors treatment response, providing a clinically applicable tool to personalize fertility-preserving therapy.
About Me
Fertility-sparing treatment of endometrial cancer, basic and clinical research of gynecological oncology.
Fertility-sparing treatment of endometrial cancer, basic and clinical research of gynecological oncology.